Incyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a company in need of more drug successes.
US biotech Melinta Therapeutics has become the latest antibiotics specialist to file for bankruptcy, after courts said it could use its lenders’ cash to keep operating until a possible sale
BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM).
